Our own in vivo findings with BAX knockout suggest that the difference in tumor response observed by He et al may not solely be through the loss of PUMA-mediated BAX activation, but potentially through the combined loss of BAX and BAK activation coupled with the loss of repressive activity against the antiapoptotic BCL2 family members. This evidence concerns the gene BBC3 and neoplasm.